Bryce Point Capital LLC Makes New Investment in Illumina, Inc. $ILMN

Bryce Point Capital LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,947 shares of the life sciences company’s stock, valued at approximately $854,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Bourgeon Capital Management LLC boosted its stake in shares of Illumina by 76.4% during the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after purchasing an additional 61,468 shares during the period. GC Wealth Management RIA LLC purchased a new position in shares of Illumina during the 2nd quarter worth about $2,289,000. waypoint wealth counsel purchased a new position in shares of Illumina during the 2nd quarter worth about $321,000. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Illumina during the 2nd quarter worth about $344,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Illumina by 171.2% during the 1st quarter. Acadian Asset Management LLC now owns 32,921 shares of the life sciences company’s stock worth $2,608,000 after purchasing an additional 20,784 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Down 2.9%

NASDAQ:ILMN opened at $119.99 on Tuesday. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The firm has a market cap of $18.44 billion, a P/E ratio of 15.19, a P/E/G ratio of 2.34 and a beta of 1.40. The firm has a 50-day simple moving average of $98.81 and a 200-day simple moving average of $93.24.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the business posted $1.14 EPS. The company’s quarterly revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent analyst reports. Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Friday. Canaccord Genuity Group boosted their price objective on shares of Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a research report on Friday. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Barclays boosted their price objective on shares of Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.